Conference Coverage

Many patients, doctors unaware of advancements in cancer care


 

Results of the doctor survey

The other survey presented at the meeting looked at how much doctors know about survival for 12 of the most common cancers.

Dr. Murphy and colleagues asked 301 noncancer doctors and 46 cancer specialists to estimate the percentage of patients who could be expected to live for 5 years after diagnosis (a measure known as the 5-year survival rate).

Answers from the two groups were compared and graded according to cancer survival statistics from the National Cancer Registry of Ireland.

Both groups of doctors had a hard time estimating the survival of common cancers.

Nononcologists accurately predicted 5-year survival for just two of the cancer types, while the cancer specialists got it right for four cancer types.

However, the noncancer doctors had a more pessimistic outlook on cancer survival generally and severely underestimated the chances of survival in specific cancers, particularly stage IV breast cancer. The survival for this cancer has “evolved considerably over time and now reaches 40% in Ireland,” Dr. Murphy pointed out.

“These results are in line with what we had expected because most physicians’ knowledge of oncology dates back to whatever education they received during their years of training, so their perceptions of cancer prognosis are likely to lag behind the major survival gains achieved in the recent past,” Dr. Murphy said.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Germline testing in advanced cancer can lead to targeted treatment
Breast Cancer ICYMI
FDA approves new indications for pembrolizumab
Breast Cancer ICYMI
Daily Recap: Lifestyle vs. genes in breast cancer showdown; Big pharma sues over insulin affordability law
Breast Cancer ICYMI
NHS England starts pilot trial of blood test for many cancers
Breast Cancer ICYMI
SNP chips deemed ‘extremely unreliable’ for identifying rare variants
Breast Cancer ICYMI
Cancer screening stopped by pandemic: Repercussions to come?
Breast Cancer ICYMI
Steroid-refractory pneumonitis from ICIs: Experience at major centers
Breast Cancer ICYMI
AHA statement flags CV risk of hormonal cancer therapies
Breast Cancer ICYMI
No survival dip with neoadjuvant letrozole-palbociclib in NeoPAL study
Breast Cancer ICYMI
Pilot study: Hybrid laser found effective for treating genitourinary syndrome of menopause
Breast Cancer ICYMI